TY - JOUR
T1 - Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging
T2 - RECIST 1.1 or Choi Criteria?
AU - Luo, Yanji
AU - Chen, Jie
AU - Huang, Kun
AU - Lin, Yuan
AU - Chen, Minhu
AU - Xu, Ling
AU - Li, Zi Ping
AU - Feng, Shi Ting
N1 - Funding Information:
This work was funded by the National Natural Science Foundation of China in the analysis, and interpretation of data, in the writing of the manuscript (81571750), the Natural Science Foundation of Guangdong Province in the design of the study (2014A030311018, 2014A030310484, 2015A030313043), and the S&T Programs of Guangdong Province in the collection of data (2014A020212125).
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/2/23
Y1 - 2017/2/23
N2 - Background: The aim of this study was to assess and compare the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and the Choi criteria in evaluating the early response of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with sunitinib. Methods: Eighteen patients with pathologically proven advanced GEP-NENs treated with sunitinib were enrolled in the study. Pre- and post-treatment CT scans (plain, biphasic enhanced CT scan) were performed on all patients. Changes in the target tumor size and density from pre-treatment to 1.4-3.1 months after treatment were measured and recorded for each patient. Tumor responses were identified using RECIST 1.1 and Choi criteria. The time to tumor progression (TTP) for each patient was measured and compared between groups using the Kaplan-Meier method. Results: Among the 18 patients, 4 (22%) exhibited a partial response (PR), 9 (50%) exhibited stable disease (SD), and 5 (28%) experienced progressive disease (PD), using RECIST 1.1. However, based on the Choi criteria, 8 (44%) patients exhibited a PR, 4 (22%) exhibited SD, and 6 (33%) experienced PD. According to RECIST 1.1, the median TTP of PR, SD and PD group were 16.6, 10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the PD group (P = 0.007) but insignificant when compared to the SD group (P = 0.131). According to Choi criteria, the median TTP of PR, SD and PD group were not reached, 10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the SD (P = 0.026) and PD groups (P < 0.001). Conclusion: The Choi criteria appear to be more sensitive and more precise than RECIST 1.1 in assessing the early response of advanced GEP-NENs treated with sunitinib.
AB - Background: The aim of this study was to assess and compare the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and the Choi criteria in evaluating the early response of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with sunitinib. Methods: Eighteen patients with pathologically proven advanced GEP-NENs treated with sunitinib were enrolled in the study. Pre- and post-treatment CT scans (plain, biphasic enhanced CT scan) were performed on all patients. Changes in the target tumor size and density from pre-treatment to 1.4-3.1 months after treatment were measured and recorded for each patient. Tumor responses were identified using RECIST 1.1 and Choi criteria. The time to tumor progression (TTP) for each patient was measured and compared between groups using the Kaplan-Meier method. Results: Among the 18 patients, 4 (22%) exhibited a partial response (PR), 9 (50%) exhibited stable disease (SD), and 5 (28%) experienced progressive disease (PD), using RECIST 1.1. However, based on the Choi criteria, 8 (44%) patients exhibited a PR, 4 (22%) exhibited SD, and 6 (33%) experienced PD. According to RECIST 1.1, the median TTP of PR, SD and PD group were 16.6, 10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the PD group (P = 0.007) but insignificant when compared to the SD group (P = 0.131). According to Choi criteria, the median TTP of PR, SD and PD group were not reached, 10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the SD (P = 0.026) and PD groups (P < 0.001). Conclusion: The Choi criteria appear to be more sensitive and more precise than RECIST 1.1 in assessing the early response of advanced GEP-NENs treated with sunitinib.
KW - Computed tomography
KW - Gastroenteropancreatic neuroendocrine neoplasms
KW - Sunitinib
KW - Time to tumor progression
UR - http://www.scopus.com/inward/record.url?scp=85013832733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013832733&partnerID=8YFLogxK
U2 - 10.1186/s12885-017-3150-7
DO - 10.1186/s12885-017-3150-7
M3 - Article
C2 - 28231773
AN - SCOPUS:85013832733
SN - 1471-2407
VL - 17
JO - BMC cancer
JF - BMC cancer
IS - 1
M1 - 154
ER -